A2290
Anti-Human IgG (γ-chain specific), F(ab′)2 fragment−Peroxidase antibody produced in goat
affinity isolated antibody, buffered aqueous solution
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
goat
conjugate
peroxidase conjugate
antibody form
affinity isolated antibody
antibody product type
secondary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
human
technique(s)
direct ELISA: 1:10,000
western blot: suitable
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Related Categories
General description
Human IgGs are glycoprotein antibodies that contain two equivalent light chains and a pair of identical heavy chains. IgGs have four distinct isoforms, ranging from IgG1 to IgG4. These antibodies regulate immunological responses to allergy and pathogenic infections. IgGs have also been implicated in complement fixation and autoimmune disorders . Anti-Human IgG (γ-chain specific), (F(ab′)2) fragment-Peroxidase antibody is specific for human IgG when tested against human IgA, IgG, IgM, Bence Jones κ, and λ myeloma proteins.
Immunogen
Purified human IgG
Application
Anti-Human IgG (γ-chain specific), (F(ab′)2) fragment-Peroxidase antibody is suitable for use in ELISA and western blot .
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Enzyme-linked immunosorbent assay (1 paper)
Enzyme-linked immunosorbent assay (1 paper)
Peroxidase-conjugated goat anti-human IgG (Fab specific) antibody was used for western blot and ELISA analysis of yeast cultures genetically modified to produced recombinant Fab fragments. Anti-Human IgG antibody was used at a 1:10,000 dilution in PBS and incubated for 1 hour at room temperature. Binding in ELISA assays was detected with a O-phenylene- diamine substrate solution (Sigma).
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4 containing 1% bovine serum albumin with preservative
Preparation Note
Prepared using the periodate method described by Wilson, M.B., and Nakane, P.K., in Immunofluorescence and Related Staining Techniques, Elsevier/North Holland Biomedical Press, Amsterdam, p215 (1978).
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
K Kiernan et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 8(9), 1829-1839 (2008-08-02)
Antibodies directed at non-gal xenoantigens are responsible for acute humoral xenograft rejection when gal knockout (GalTKO) pig organs are transplanted into nonhuman primates. We generated IgM and IgG gene libraries using peripheral blood lymphocytes of rhesus monkeys initiating active xenoantibody
Joanne L Zahorsky-Reeves et al.
Xenotransplantation, 14(2), 135-144 (2007-03-27)
Recent work has indicated a role for anti-Gal alpha 1-3Gal (Gal) and anti-non-Gal xenoantibodies in the primate humoral rejection response against human-decay accelerating factor (hDAF) transgenic pig organs. Our laboratory has shown that anti-porcine xenograft antibodies in humans and non-human
Philippe Gatault et al.
mAbs, 7(6), 1205-1211 (2015-09-05)
The annual cost of eculizumab maintenance therapy in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic-uremic syndrome (aHUS) exceeds $300,000 per patient. A better understanding of eculizumab pharmacokinetics and subsequent individual dose adjustment could reduce this cost. We measured the trough
Nils Mülling et al.
Infection (2023-05-27)
Vaccination against Streptococcus pneumoniae is recommended in transplant recipients to reduce the morbidity and mortality from invasive pneumococcal disease. Previous studies indicate that transplant recipients can produce specific antibodies after vaccination with the 13-valent pneumococcal conjugate vaccine Prevenar 13 (PCV13)
Junzo Nojima et al.
Clinical chemistry, 51(3), 545-552 (2005-01-08)
Venous thromboembolic events such as deep vein thrombosis and pulmonary embolism are common manifestations of antiphospholipid syndrome. Our aim was to clarify the roles of anti-phospholipid (aPL) antibodies in the pathogenesis of venous thromboembolism (VTE) in patients with systemic lupus
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service